Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2015

01-03-2015

Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma

Authors: Shelly M. Seward, Ira Winer

Published in: Cancer and Metastasis Reviews | Issue 1/2015

Login to get access

Abstract

Surgery and chemotherapy are the standard of care for epithelial ovarian cancer, and it is well established that survival outcomes are improved when the surgery results in no or optimal (less than 1 cm) residual disease. However, for patients with bulky disease that may require extensive or radical procedures to accomplish this goal, the use of neoadjuvant chemotherapy followed by interval debulking surgery to simplify the surgery and minimize morbidity has been suggested. Arguably, this is only ideal if this process produces survival outcomes equivalent to those of primary debulking surgery. The purpose of this article is to review the data surrounding this controversial topic.
Literature
1.
Cancer Facts & Figures. (2014). Atlanta: American Cancer Society; 2014.
2.
Buys, S.S., Partridge, E., Black, A., Johnson, C.C., Lamerato, I., Isaacs, C. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. Journal of the American Medical Association. 2295–303.
3.
Menon, U.G-M.A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., Godfrey, K., Oram, D., Herod, J., Williamson, K., Seif, MW., Scott, I., Mould, T., Woolas, R., Murdoch, J., Dobbs, S., Amso, NN., Leeson, S., Cruickshank, D., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology. 327–40.
4.
Kurman, R.J., Shih, I.M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Human Pathology. 918–31.
5.
Griffiths, C. (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monographs. 101–4.
6.
Hoskins, W. J., Bundy, B. N., Thigpen, J. T., & Omura, G. A. (1992). The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecologic Oncology, 47(2), 159–62.CrossRefPubMed
7.
Hoskins, W.J., Creasman, M.W., Grady, M.F., Homesley, H.D., Creasman, W.T., Berman, M., Ball, H., Berek, J.S. (1994). The effect of tumor diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology. 974–9.
8.
Fader, A. N., & Rose, P. (2007). Role of surgery in ovarian carcinoma. Journal of Clinical Oncology, 25(20), 2873–83.CrossRefPubMed
9.
Bristow, R. E., Tomacruz, R., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology, 20(5), 1248–59.CrossRefPubMed
10.
Chang, S. J., Bristow, R., & Ryu, H. S. (2012). Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in ovarian cancer. Annals of Surgical Oncology, 19, 4059–67.CrossRefPubMed
11.
Winter, W. E., Maxwell, G., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M., Armstrong, D. K., Muggia, F., & McGuire, W. P. (2007). Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology study group. Journal of Clincial Oncology, 25(24), 3621–7.CrossRef
12.
du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., & Pfisterer, J. (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 115, 1234–44.CrossRefPubMed
13.
Elattar, A., Bryant, A., Winter-Roach, B.A., Hatem, M., Naik, R. (2011). Optimal primary surgical treatment for advanced epithelial ovarian cancer (Review). Cochrane Database Systematic Review. 2011.
14.
Vergote, I. B., De Wever, I., Decloedt, J., Tjalma, W., Van Gramberen, M., & van Dam, P. (2000). Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology, 27(3 Suppl 7), 31–6.PubMed
15.
Schwartz, P. E., Chambers, J. T., & Makuch, R. (1994). Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology, 53(1), 33–7.CrossRefPubMed
16.
Bristow, R., & Chi, D. S. (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology, 103, 1070–6.CrossRefPubMed
17.
18.
Aletti, G. D., Dowdy, S., Gostout, B. S., Jones, M. B., Stanhope, C. R., Wilson, T. O., Podratz, K. C., & Kliby, W. A. (2006). Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and Gynecology, 107(1), 77–85.CrossRefPubMed
19.
Vergote, I. T. C., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H., van der Burg, M., Lacave, A. J., Panici, P. B., Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G., Pecorelli, S., & Reed, N. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 363(10), 943–53.CrossRefPubMed
20.
McGuire, W. P., Hoskins, W., Brady, M. F., Kugera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New England Journal of Medicine, 334(1), 1–6.CrossRefPubMed
21.
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354, 34–43.CrossRefPubMed
22.
Chi, D. S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitao, M., Levine, D., Gardner, G., Abu-Rustum, N., & Barakat, R. (2012). An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecologic Oncology, 124, 10–4.CrossRefPubMed
23.
Kehoe, S., Hook, J., Nankivell, M., et al. (2013). Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial.; 2013; Chicago: 2013 ASCO Annual Meeting, Abstract 5500.
24.
Aletti, G. D., Gostout, B., Podratz, K. C., & Cliby, W. A. (2006). Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecologic Oncology, 100, 33–7.CrossRefPubMed
25.
Eisenkop, S. M., & Spirtos, N. (2001). Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecologic Oncology, 82, 435–41.CrossRefPubMed
Metadata
Title
Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
Authors
Shelly M. Seward
Ira Winer
Publication date
01-03-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-014-9536-y

Other articles of this Issue 1/2015

Cancer and Metastasis Reviews 1/2015 Go to the issue

EditorialNotes

Preface

Clinical

Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring

OriginalPaper

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

Clinical

HER2 expression status in diverse cancers: review of results from 37,992 patients

OriginalPaper

RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer

Clinical

Immunotherapy of melanoma: Present options and future promises
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits